Oligonucleotide therapeutics are transforming drug development, but their complex pharmacology and regulatory landscape present unique challenges. Hear Certara and Ionis Pharmaceutical experts as we explore a model-informed approach to accelerating oligonucleotide drug development.
In this webinar, our experts covered:
- Essential foundations of oligonucleotide therapeutics – what they are, how they work, and why they matter
- Regulatory strategies for success from day one – ensuring alignment with evolving global expectations
- How model-informed drug development (MIDD) accelerates and de-risks oligonucleotide programs – smarter decisions through data-driven insights
We showcased our collaboration with Ionis Pharmaceuticals, highlighting how our innovative modeling and regulatory strategies helped accelerate their oligonucleotide program. Through this real-world example, viewers gained insights into how Certara de-risks development, speeds approvals, and maximizes market access. Don’t miss the chance to learn from industry leaders and refine your oligonucleotide development strategy. Watch the webinar on demand now.
